– USA, CA – Viewics, Inc., a healthcare analytics and data platform company, announced today that it has secured an additional $8 million in funding, led by Canvas Venture Fund. Canvas brings Viewics strategic guidance and access to a vast network of partners to support its growing healthcare client base. Changes in the healthcare environment have led to significant demand for Viewics’ analytics solutions and this funding will enable continued growth and product innovation.
Viewics offers a suite of analytics solutions on a data platform that enables healthcare organizations to execute on their clinical and operational strategies. Viewics delivers a packaged Software as a Service (SaaS) solution that gives leaders instant access to the information they need without the time, expense, and complexity of existing tools.
“We are excited to be part of the data strategy at leading healthcare institutions across the US and Canada. Our data aggregation technology has become integral to our customers with over 80% of them significantly expanding on their initial scope within months of use. It is critical in today’s healthcare environment to strive for improved care and efficiency. We plan to continue investing in our technology and people to support the needs of our customers in these endeavors,” said Dhiren Bhatia, Viewics CEO and founder.
Key facts about Viewics
“Viewics is transforming the way hospitals use data to grow revenues and reduce expenses,” said Rebecca Lynn, General Partner at Canvas. “I’ve been tracking Viewics for four years, and am impressed with the prestigious customers they have attracted. Their approach uniquely integrates data from different silos within a healthcare organization – finance, labs, sales, marketing – without burdening a hospital’s internal IT department. It’s all about data. You can’t chart where you want to go until you measure where you are. In order to do that, you need full access to all your data. Viewics does that with a powerful SaaS analytics platform, and have gained the trust of their customers as a result.”
Along with Ash Patel of Morado Venture Partners, Lynn will be joining the board of directors at Viewics. She led early-stage investments in Practice Fusion, Doximity, and HealthLoop, and is the creator of a signature digital-health conference called “DC to VC” which brings together Washington, DC policy makers with VCs and startups to grow innovation in the healthcare space.
Based in the heart of Silicon Valley, Viewics, Inc. is an innovator in healthcare analytics and business intelligence. Viewics enables organizations to aggregate, extract and share insights from the vast amounts of data in their information systems. The company’s flagship product, Viewics Health Insighter (VHI), is a cloud-based, software-as-a-service platform that delivers an immediate ROI for organizations through enhanced operational, clinical and financial outcomes.
Canvas is a Menlo Park-based venture capital firm focused on making early-stage investments in software and services. Spun out from Morgenthaler Ventures in August 2013, Canvas was initially managed by Rebecca Lynn, Gary Little and Gary Morgenthaler. Paul Hsiaojoined as general partner in May 2014. Previous to Canvas, these partners led early investments in companies such as Lending Club, Evernote, Siri, Houzz, MuleSoft, Elance-oDesk, Practice Fusion, and Doximity. Canvas has made the following investments since raising its inaugural fund: Viewics, HealthLoop, CrowdFlower, FutureAdvisor and Totango. With its thesis-based approach to investing, Canvas continues to establish itself as the go-to VC firm for digital health, financial services, marketplaces, enterprise SaaS, big data, and machine learning.
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
Comments are closed.